Why Performance Food Shares Are Gaining Today

Performance Food Group Co (NYSE: PFGC) reported Q4 FY23 sales growth of 1.9% Y/Y to $14.87 billion, missing the consensus of $15.07 billion. Net sales benefitted from a positive channel mix, higher cases sold, and increased selling price per case due to inflation.

Performance Food Group Co (NYSE:PFGC) reported Q4 FY23 sales growth of 1.9% Y/Y to $14.87 billion, missing the consensus of $15.07 billion.

Net sales benefitted from a positive channel mix, higher cases sold, and increased selling price per case due to inflation.

Net sales for Foodservice decreased 1.1% Y/Y to $7.3 billion, Vistar increased 18.3% Y/Y to $1.2 billion, and Convenience rose 2.3% Y/Y to $6.3 billion.

Total organic case volume grew 1.8% Y/Y, led by a 7.6% Y/Y increase in organic independent cases, higher Performance Brands cases, and growth across Vistar’s channels.

Gross profit increased 12.0% Y/Y to $1.7 billion, aided by a favorable shift in the cases sold mix and improved independent channel. Operating expenses rose 5.2% Y/Y to $1.4 billion.

Adjusted EBITDA grew 7.9% Y/Y to $385.2 million in the quarter. 

Adjusted EPS increased 6.5% Y/Y to $1.14, in line with the consensus.

The company held $20 million in cash and equivalents as of July 1, 2023. Operating cash flow totaled $832.1 million at the end of the year.

Repurchase: In Q4, the company bought back shares worth $11.2 million. As of July 1, 2023, the company had approximately $288.8 million worth of shares remaining available for share repurchases.

Outlook: The company expects Q1 FY24 net sales of $14.7 billion-$15.0 billion (consensus $15.22 billion) and adjusted EBITDA of $360 million-$380 million.

For FY24, PFGC expects net sales of $59 billion-$60 billion (consensus $59.97 billion) and adjusted EBITDA of $1.45 billion-$1.5 billion.

The company reiterated its previously announced 3-year net sales and adjusted EBITDA targets, expecting annual net sales of $62 billion – $64 billion and adjusted EBITDA of $1.5 billion – $1.7 billion in fiscal 2025.

Price Action: PFGC shares are trading higher by 8.2% at $62.19 on the last check Wednesday.

Total
0
Shares
Related Posts
Read More

Eisai And Biogen Announced FDA Accepts Filing of LEQEMBI Supplemental Biologics License Application For IV Maintenance Dosing To Treat Early Alzheimer’s Disease

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen")) announced today that the U.S.Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc.

BIIB